T cell ther­a­py play­er Lyell pre­pares to open $65M man­u­fac­tur­ing fa­cil­i­ty in the Seat­tle area

When Stephen Hill was liv­ing in Puer­to Ri­co and Mary­land, over­see­ing the drug man­u­fac­tur­ing arms for Am­gen and As­traZeneca, each pho­to his fam­i­ly post­ed on Face­book made him miss his home state of Wash­ing­ton a lit­tle bit more. His dad stand­ing in a riv­er, hold­ing a fresh­ly caught steel­head trout. Oth­ers mak­ing fresh ap­ple cider at his grand­fa­ther’s farm.

But to­day, Hill’s back home, over­see­ing the open­ing of Lyell Im­munophar­ma’s new $65 mil­lion man­u­fac­tur­ing cen­ter as the firm’s chief tech­ni­cal op­er­a­tions of­fi­cer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN